Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for research purposes. This synthetic peptide mimics the action of endogenous incretins to potentially enhance insulin secretion, suppress glucagon levels, and delay gastric emptying.
The compound features a 39-amino acid peptide backbone with specific modifications including two non-natural residues (Aib at positions 2 and 13) and a C20 fatty diacid side chain at Lys20, contributing to its extended research potential.
For research purposes, typical parameters include initial testing at 2.5mg with potential escalation to 15mg based on experimental requirements. The peptide demonstrates particular interest in metabolic research applications.
Our production facilities maintain strict quality control measures including HPLC purity verification, mass spectrometry confirmation, and amino acid analysis to ensure batch-to-batch consistency for research applications.
Available packaging options include 10 vials per box configuration, with customization available for bulk research orders. The lyophilized powder formulation ensures stability during transport and storage.
Note: This product is intended for research use only, not for human consumption. Proper handling procedures should be followed by qualified researchers in controlled laboratory settings.